These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24047518)

  • 1. Microglia--a therapeutic target in neurological diseases and disorders.
    Kaur C; Ling EA
    CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):719. PubMed ID: 24047518
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential drugs targeting microglia: current knowledge and future prospects.
    Rangarajan P; Eng-Ang L; Dheen ST
    CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):799-806. PubMed ID: 24047522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between the chemokine receptor CCR5 and microglia in neurological disorders: consequences of targeting CCR5 on neuroinflammation, neuronal death and regeneration in a model of epilepsy.
    Louboutin JP; Strayer DS
    CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):815-29. PubMed ID: 24047524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases.
    Skundric DS
    Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167
    [No Abstract]   [Full Text] [Related]  

  • 5. [The Role of Microglia in Neuroinflammation].
    Suzumura A
    Brain Nerve; 2017 Sep; 69(9):975-984. PubMed ID: 28900060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer-based drug delivery devices for neurological disorders.
    Halliday AJ; Cook MJ
    CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):205-21. PubMed ID: 19601818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target.
    Du L; Zhang Y; Chen Y; Zhu J; Yang Y; Zhang HL
    Mol Neurobiol; 2017 Dec; 54(10):7567-7584. PubMed ID: 27830532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: Therapeutic implications.
    Bolaños JP; Moro MA; Lizasoain I; Almeida A
    Adv Drug Deliv Rev; 2009 Nov; 61(14):1299-315. PubMed ID: 19716390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ion channels in monocytes and microglia/brain macrophages: promising therapeutic targets for neurological diseases.
    Eder C
    J Neuroimmunol; 2010 Jul; 224(1-2):51-5. PubMed ID: 20554024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs as CNS Drug Targets.
    Gurwitz D
    Drug Dev Res; 2016 Nov; 77(7):331-335. PubMed ID: 27569840
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders.
    Bhattacharya A; Ceusters M
    Neuropsychopharmacology; 2020 Jan; 45(1):234-235. PubMed ID: 31477815
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting kinin receptors for the treatment of neurological diseases.
    Rodi D; Couture R; Ongali B; Simonato M
    Curr Pharm Des; 2005; 11(10):1313-26. PubMed ID: 15853687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modifying protein misfolding.
    Jones D
    Nat Rev Drug Discov; 2010 Nov; 9(11):825-7. PubMed ID: 21030987
    [No Abstract]   [Full Text] [Related]  

  • 14. GLT-1 transporter: an effective pharmacological target for various neurological disorders.
    Soni N; Reddy BV; Kumar P
    Pharmacol Biochem Behav; 2014 Dec; 127():70-81. PubMed ID: 25312503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New frontiers in G protein-coupled receptor regulation of neurological disorders.
    Maudsley S
    CNS Neurol Disord Drug Targets; 2010 Nov; 9(5):525. PubMed ID: 20632974
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting epigenetics in nervous system disease.
    Zhang R; Lu J; Kong X; Jin L; Luo C
    CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):126-41. PubMed ID: 23244434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kynurenines and the nervous system: therapeutic perspectives.
    Vécsei L
    J Neural Transm (Vienna); 2012 Feb; 119(2):107. PubMed ID: 22160490
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma.
    Bosco A; Inman DM; Steele MR; Wu G; Soto I; Marsh-Armstrong N; Hubbard WC; Calkins DJ; Horner PJ; Vetter ML
    Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1437-46. PubMed ID: 18385061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The promise of minocycline in neurology.
    Yong VW; Wells J; Giuliani F; Casha S; Power C; Metz LM
    Lancet Neurol; 2004 Dec; 3(12):744-51. PubMed ID: 15556807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trace amine receptors as targets for novel therapeutics: legend, myth and fact.
    Branchek TA; Blackburn TP
    Curr Opin Pharmacol; 2003 Feb; 3(1):90-7. PubMed ID: 12550748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.